Resignation of CEO
SkinBioTherapeutics plc announced the resignation of its CEO, Stuart Ashman, following his suspension by the Board pending an investigation into his conduct. The Non-Executive Chairman, Martin Hunt, will temporarily assume the role of Executive Chairman, supported by the leadership team, while the company initiates a search for both an interim and a permanent CEO. The company stated it will provide further updates to the market in due course.
Select text to share a quote on X · sign in to keep highlights & notes in your SBTX notes
13 February 2026 - SkinBioTherapeutics plc, (AIM: SBTX), the life science business focused on skin health, announces that CEO, Stuart Ashman, has resigned, having been suspended by the Board pending an investigation into matters relating to his conduct. The Company is undertaking a full investigation, supported by its professional advisors.
Martin Hunt, Non-Executive Chairman, will assume the role and responsibilities of Executive Chairman temporarily; he will be supported by the rest of the Board and Leadership team to provide business leadership and continuity. The Company has instigated a search to find an interim CEO to appoint as soon as possible, and to find a new, permanent CEO for the longer term.
The Company will update the Market and shareholders in due course. Until then, there will be no further comment at this time.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.